Dr. James Lund Mcdaniel MD

Recommended Articles

• Chronic Bronchitis – The Smoker’s Cough

  What is chronic bronchitis?Chronic bronchitis is defined as a persistent cough with sputum production for at least three months in at least two consecutive years in the absence of any other identifiable causes.Chronic bronchitis is also commonly known as the smoker’s cough. This is due to the fact...

• Community-Acquired Pneumonia: Causes, Symptoms, and Management

  Community-acquired pneumonia (CAP) refers to pneumonia that develops in people with very less or no contact with any medical setting such as a hospital or clinic. Most of the time, the people who are infected with CAP are healthy individuals.Background of the DiseaseFour million cases...

• Study Concludes At-home Antibiotic Therapy for Cystic Fibrosis No Riskier than at Hospital

  Many patients would generally perform to have their treatments done at home than in a hospital; it's a familiar place, the patient can be more comfortable, travel isn’t necessary. It was assumed, however, that intravenous antibiotic treatment for cystic fibrosis patients would not be as safe at...

• A Cystic Fibrosis App to Bring Data to Market

  For many people with CF, remembering their daily treatment regimens and medication schedules can seem daunting and difficult. Most patients acclaim that if they had a resource, such as an app, that would make their health management easier to handle, that they would love to try it. In addition to...

• Radiologists Look for Patterns in Cystic Fibrosis as More Adults Are Diagnosed

  Recent research shows that there is an increasing number of adults being diagnosed with cystic fibrosis. This information is leading scientists to believe cystic fibrosis is now just as much of an adult condition as a childhood condition. This increase has caused scientists and radiologists to...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...